SCHEMBL14858735

SCHEMBL14858735

CC1C2CC3(C)CC(C)(C2)CC1(OC=O)C3

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3915510 0.68 GRIN2D (0.31)
SCHEMBL8940989 0.66 GRIN1 (0.36)
SCHEMBL3162219 0.65 GRIN1 (0.42)
SCHEMBL17414866 0.62
SCHEMBL14858977 0.59 MEN1 (0.31)
SCHEMBL12837024 0.58
SCHEMBL2549983 0.58 GRIN1 (0.35)
SCHEMBL15775088 0.57 SLC22A2 (0.30)
SCHEMBL11114845 0.56
SCHEMBL6654181 0.55 GRIN1 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240285611-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC. (US) 2024-08-29 US disclosed
US-11786519-B2 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases ABBVIE INC. (US) 2023-10-17 US disclosed
US-20210228565-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC. (US) 2021-07-29 US disclosed
US-20200253954-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC. (US) 2020-08-13 US disclosed
US-20180140595-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC (US) 2018-05-24 US disclosed
US-9844547-B2 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases ABBVIE INC. (US) 2017-12-19 US disclosed
US-20170296531-A9 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC (US) 2017-10-19 US disclosed
EP-2766361-B1 8-CARBAMOYL-2-(2,3-DISUBSTITUTED PYRID-6-YL)-1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES AS APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC (US) 2016-08-10 EP disclosed
US-20160158218-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC (US) 2016-06-09 US disclosed
US-9227963-B2 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases ABBVIE INC. (US) 2016-01-05 US disclosed
US-20150072978-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC (US) 2015-03-12 US disclosed
US-8889675-B2 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases ABBVIE INC. (US) 2014-11-18 US disclosed
EP-2766361-A1 8 - CARBAMOYL - 2 - (2,3- DI SUBSTITUTED PYRID - 6 - YL) -1,2,3,4 -TETRAHYDROISOQUINOLINE DERIVATIVES AS APOPTOSIS - INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES AbbVie Inc. (US) 2014-08-20 EP disclosed
WO-2013055897-A1 8 - CARBAMOYL - 2 - (2,3- DI SUBSTITUTED PYRID - 6 - YL) -1,2,3,4 -TETRAHYDROISOQUINOLINE DERIVATIVES AS APOPTOSIS - INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC. (US) 2013-04-18 WO disclosed
US-20130096120-A1 APOPTOSIS-INDUCED AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC. (US) 2013-04-18 US disclosed